Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively (From 1/7/2009) and Prospectively (up to 31/12/2013) as First Line Treatment for Patients With Locally Advanced or Metastatic Colorectal Cancer (With or Without KRAS Mutation). Assessment of Toxicity, Compliance and Survival of Patients.
In addition investigators propose to assess the compliance of patients to treatment and the
efficacy of treatment. That means percentage of objective responses, duration of response,
frequency of curative liver resection after the administration of treatment, progression
free survival and estimation of overall survival
Observational Model: Cohort
Number of Participants with AE
In this observational study investigators are going to assess standard schedules in which administration was every 2 weeks.
Every 2 weeks up to 12 weeks
Vassilis Georgoulias, MD
Hellenic Oncology Research Group
Greece: National Organization of Medicines